Fibrovein 3%    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
279Huge venous malformation with cervical, oral and pharyngeal diffuse lesion1

279. Huge venous malformation with cervical, oral and pharyngeal diffuse lesion    [ 12 clinical trials,   23 drugs,   (DrugBank: 9 drugs),   3 drug target genes,   103 drug target pathways]
Searched query = "Huge venous malformation with cervical, oral and pharyngeal diffuse lesion", "Huge venous malformation", "Venous malformation"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 12 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2011-001455-37-NO
(EUCTR)
21/12/201101/06/2011Prospective randomized interventional study in patients with venous malformations.Prospective randomized interventional study. Compare the effect of bleomycin and Tetradecyl Sodium Sulphate (Fibrovein) in the treatment of venous malformations. Clinical neurological and neurophysiological study of a subpopulation of patients with venous malformations. Venous malformation
MedDRA version: 13.1;Level: LLT;Classification code 10047229;Term: Venous malformation NOS;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Bleomycin Baxter
Product Name: Bleomycin
Trade Name: Fibrovein 3%
Product Name: Fibrovein 3%
Department of Radiology, Oslo University Hospital, NorwayNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Norway